Additionally, in a study on chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL1–negative) CML in patients with CSF3R mutations, CSF3R truncating mutations were found to be sensitive to dasatinib [50] suggesting that the trial of SRC kinase inhibitors is a reasonable approach [51]. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.